102 related articles for article (PubMed ID: 3859213)
1. Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin.
Birnbaum J; Kahan FM; Kropp H; MacDonald JS
Am J Med; 1985 Jun; 78(6A):3-21. PubMed ID: 3859213
[TBL] [Abstract][Full Text] [Related]
2. Carbapenems: past, present, and future.
Papp-Wallace KM; Endimiani A; Taracila MA; Bonomo RA
Antimicrob Agents Chemother; 2011 Nov; 55(11):4943-60. PubMed ID: 21859938
[TBL] [Abstract][Full Text] [Related]
3. Definition of the common and divergent steps in carbapenem β-lactam antibiotic biosynthesis.
Bodner MJ; Li R; Phelan RM; Freeman MF; Moshos KA; Lloyd EP; Townsend CA
Chembiochem; 2011 Sep; 12(14):2159-65. PubMed ID: 21913298
[TBL] [Abstract][Full Text] [Related]
4. Non-heme iron oxygenases generate natural structural diversity in carbapenem antibiotics.
Bodner MJ; Phelan RM; Freeman MF; Li R; Townsend CA
J Am Chem Soc; 2010 Jan; 132(1):12-3. PubMed ID: 20017478
[TBL] [Abstract][Full Text] [Related]
5. Thienamycin: development of imipenen-cilastatin.
Kahan FM; Kropp H; Sundelof JG; Birnbaum J
J Antimicrob Chemother; 1983 Dec; 12 Suppl D():1-35. PubMed ID: 6365872
[TBL] [Abstract][Full Text] [Related]
6. Thienamycin, a new beta-lactam antibiotic. I. Discovery, taxonomy, isolation and physical properties.
Kahan JS; Kahan FM; Goegelman R; Currie SA; Jackson M; Stapley EO; Miller TW; Miller AK; Hendlin D; Mochales S; Hernandez S; Woodruff HB; Birnbaum J
J Antibiot (Tokyo); 1979 Jan; 32(1):1-12. PubMed ID: 761989
[TBL] [Abstract][Full Text] [Related]
7. Imipenem/cilastatin: the first carbapenem antibiotic.
Lyon JA
Drug Intell Clin Pharm; 1985 Dec; 19(12):895-9. PubMed ID: 3910385
[TBL] [Abstract][Full Text] [Related]
8. Naturally-occurring beta-lactamase inhibitors with antibacterial activity.
Brown AG; Butterworth D; Cole M; Hanscomb G; Hood JD; Reading C; Rolinson GN
J Antibiot (Tokyo); 1976 Jun; 29(6):668-9. PubMed ID: 950324
[No Abstract] [Full Text] [Related]
9. Potent activity of meropenem against Escherichia coli arising from its simultaneous binding to penicillin-binding proteins 2 and 3.
Sumita Y; Fukasawa M
J Antimicrob Chemother; 1995 Jul; 36(1):53-64. PubMed ID: 8537284
[TBL] [Abstract][Full Text] [Related]
10. Studies on the mechanism of action of imipenem (N-formimidoylthienamycin) in vitro: binding to the penicillin-binding proteins (PBPs) in Escherichia coli and Pseudomonas aeruginosa, and inhibition of enzyme activities due to the PBPs in E. coli.
Hashizume T; Ishino F; Nakagawa J; Tamaki S; Matsuhashi M
J Antibiot (Tokyo); 1984 Apr; 37(4):394-400. PubMed ID: 6427167
[TBL] [Abstract][Full Text] [Related]
11. Optimizing Betalactam Clinical Response by Using a Continuous Infusion: A Comprehensive Review.
Diamantis S; Chakvetadze C; de Pontfarcy A; Matta M
Antibiotics (Basel); 2023 Jun; 12(6):. PubMed ID: 37370371
[TBL] [Abstract][Full Text] [Related]
12. Natural detoxification of antibiotics in the environment: A one health perspective.
Baquero F; Coque TM; Martínez JL
Front Microbiol; 2022; 13():1062399. PubMed ID: 36504820
[TBL] [Abstract][Full Text] [Related]
13. JBP485, A Dual Inhibitor of Organic Anion Transporters (OATs) and Renal Dehydropeptidase-I (DHP-I), Protects Against Imipenem-Induced Nephrotoxicity.
Wang C; Wang C; Wu J; Meng Q; Jin H; Sun H; Kaku T; Chen J; Huo X; Liu K
Front Pharmacol; 2022; 13():938813. PubMed ID: 35754503
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of Action of Carbapenem Resistance.
Aurilio C; Sansone P; Barbarisi M; Pota V; Giaccari LG; Coppolino F; Barbarisi A; Passavanti MB; Pace MC
Antibiotics (Basel); 2022 Mar; 11(3):. PubMed ID: 35326884
[TBL] [Abstract][Full Text] [Related]
15. Nanotechnology as a Novel Approach in Combating Microbes Providing an Alternative to Antibiotics.
Mubeen B; Ansar AN; Rasool R; Ullah I; Imam SS; Alshehri S; Ghoneim MM; Alzarea SI; Nadeem MS; Kazmi I
Antibiotics (Basel); 2021 Nov; 10(12):. PubMed ID: 34943685
[TBL] [Abstract][Full Text] [Related]
16. Impact of carbapenem resistance on mortality in patients infected with
Zhou R; Fang X; Zhang J; Zheng X; Shangguan S; Chen S; Shen Y; Liu Z; Li J; Zhang R; Shen J; Walsh TR; Wang Y
BMJ Open; 2021 Dec; 11(12):e054971. PubMed ID: 34907071
[TBL] [Abstract][Full Text] [Related]
17. KPC-2 β-lactamase enables carbapenem antibiotic resistance through fast deacylation of the covalent intermediate.
Mehta SC; Furey IM; Pemberton OA; Boragine DM; Chen Y; Palzkill T
J Biol Chem; 2021; 296():100155. PubMed ID: 33273017
[TBL] [Abstract][Full Text] [Related]
18. Structure and Molecular Recognition Mechanism of IMP-13 Metallo-β-Lactamase.
Softley CA; Zak KM; Bostock MJ; Fino R; Zhou RX; Kolonko M; Mejdi-Nitiu R; Meyer H; Sattler M; Popowicz GM
Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32205343
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
